Pioglitazone HCl是一种选择性过氧化物酶体增殖物激活受体γ激动剂，能通过抑制线粒体铁摄取及脂质过氧化进而阻断铁死亡过程。
| 英文别名 (English Synonym) | Pioglitazone HCl |
| 中文名称 (Chinese Name) | 盐酸吡格列酮 |
| 靶点 (Target) | PPAR |
| 通路 (Pathway) | Protease/Metabolic Enzyme |
| CAS号 (CAS NO.) | 112529-15-4 |
| 分子式 (Formula) | C19H20N2O3S·HCl |
| 分子量 (Molecular Weight) | 392.9 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] vPuddu A, Sanguineti R, Durante A, Viviani GL. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84. doi: 10.1016/j.regpep.2012.05.089. Epub 2012 May 12. PMID: 22587907.[2]Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55. doi: 10.1074/jbc.M505649200. Epub 2006 Jan 23. PMID: 16431926.[3]Elrashidy RA, Asker ME, Mohamed HE. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. doi: 10.1177/1074248411431581. Epub 2012 Jan 18. Retraction in: J Cardiovasc Pharmacol Ther. 2025 Jan-Dec;30:10742484251381292. doi: 10.1177/10742484251381292. PMID: 22261714.
